The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.

Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.

FDA clears skin-cancer companion diagnostic. Medtronic announces two AAA-related approvals. OrbusNeich launches dual-therapy stent outside the U.S. More new products.